OBJECTIVES:To evaluate the real-world effectiveness of rituximab (RTX) and intravenous cyclophosphamide (IVCY) compared to non-use for remission induction in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). METHODS:This observational study emulated a target trial using data from the Japan Collaborative Registry of ANCA-associated Vasculitis. Patients aged ≥20 years with newly diagnosed or relapsing MPA or GPA (2017-23) were included. RTX or IVCY use within 4 weeks defined the treatment group; others formed the control group. The primary outcome was failure to achieve remission at week 24 (Birmingham Vasculitis Activity Score = 0 and prednisolone ≤ 10 mg/day). Secondary outcomes included a composite of death, kidney failure, and relapse, and serious infection. In inverse probability weighted population, risk ratios were estimated using modified Poisson regression. RESULTS:Among 544 patients (MPA: 413, GPA: 131), 63.6% received RTX or IVCY. The risk ratio for failure to achieve remission was 0.72 (95% CI: 0.61-0.85), and for the composite outcome was 0.57 (95% CI: 0.33-0.97), and for serious infection was 1.03 (95% CI: 0.47-2.25). Results were robust in sensitivity analyses. CONCLUSIONS:RTX and IVCY improved short-term outcomes in MPA and GPA without increasing infection risk, supporting their recommendation as standard therapy.
Objectives To develop a simple, interpretable dose-volume histogram prediction model for intensity-modulated radiation therapy by integrating distance-to-target histograms with longitudinal spatial features, and to evaluate its accuracy and generalizability.Methods Using prostate cancer cases, dose-volume histograms for the rectum and bladder (excluding overlaps with the planning target volume) were predicted via nonlinear regression based on slice-specific dose-to-distance relationships derived using a signed longitudinal distance metric. The model was validated on 70 internal cases and 10 external cases from a public database. Prediction accuracy was assessed using mean absolute error (MAE) and mean dose differences. To assess clinical utility, 5 outlier cases per organ were replanned using model predictions as guidance.Results Internal validation showed average MAEs of 3.33% and 3.16% for the rectum and bladder, respectively, with mean dose differences within 0.3 Gy. External validation confirmed robustness, yielding MAEs of 3.45% and 2.12%. Replanning the outlier cases successfully reduced the mean dose by a median of 5.44 Gy for the rectum and 3.04 Gy for the bladder. These actual dosimetric gains correlated with the predicted room for improvement (Pearson's r = 0.85).Conclusions The proposed model achieved high accuracy across independent cohorts. Its transparency and simplicity make it a reliable tool for routine quality assurance, identifying suboptimal plans, and guiding dosimetric optimization.Advances in knowledge Incorporating a signed longitudinal distance metric into distance-to-target histograms achieves accurate and generalizable dose predictions. This approach provides a transparent, highly interpretable alternative to "black box" deep learning models.
Glucocorticoid tapering in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis has been accelerated, whereas avacopan offers an alternative despite trial retraction. However, whether these regimens are safely implemented in routine practice remains uncertain. We analysed 774 induction episodes of microscopic polyangiitis or granulomatosis with polyangiitis from the J-CANVAS registry (2017–2023), classifying tapering speed at week 8 according to whether the dose was at or below the PEXIVAS reduced-dose target, with overlap weighting on 15 covariates; the primary outcome was 52-week relapse. The faster-taper group received 1448 mg less cumulative prednisolone over weeks 0–24 than the slower-taper group, with a trend toward a higher risk of relapse (hazard ratio, 1.53; 95
OBJECTIVES:Rituximab (RTX) is a standard maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Its efficacy in Japan remains unclear, where microscopic polyangiitis (MPA) predominates and clinical characteristics differ from Western-dominated randomized controlled trial (RCT) populations. METHODS:Japanese patients with MPA or granulomatosis with polyangiitis (GPA) enrolled in a nationwide registry were included. Exposure was RTX use during maintenance therapy. The primary endpoint was major relapse-free survival at 104 weeks. The secondary endpoint was any relapse-free survival (major or minor) at 104 weeks. Baseline differences were adjusted using inverse probability of treatment weighting based on key demographic and disease-related covariates. RESULTS:A total of 389 patients were analysed, with 85 in the RTX group. The RTX group included a higher proportion of GPA cases (37/85 vs. 74/304), resulting in baseline imbalance. After inverse probability of treatment weighting, no major relapses were observed in the RTX group, whereas the major relapse-free survival at 104 weeks was 94.8% in the non-RTX group. The RTX group showed significantly higher any relapse-free survival at 104 weeks (95.4% versus 83.3%; HR for any relapse, 0.27; 95% CI, 0.09-0.74; P = .02). CONCLUSIONS:Our findings suggest that RTX may be an effective option for remission maintenance in Japanese patients with MPA or GPA.